Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL381002

O=C(O)C(F)(F)F.O=C(c1ccc(-c2cc(Cl)c(C[C@@H]3CCN(C4CCNCC4)C3=O)c(Cl)c2)cc1)N1CCC(C(F)(F)F)CC1

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.39
RAD52 P43351 1/20 0.39
UBE2N P61088 1/20 0.39
TPSAB1 Q15661 1/20 0.36
TPSD1 Q9BZJ3 1/20 0.36
TPSG1 Q9NRR2 1/20 0.36
HTR2B P41595 2/20 0.35
SPR P35270 6/20 0.34
L3MBTL3 Q96JM7 1/20 0.34
NAMPT P43490 1/20 0.34
F10 P00742 1/20 0.34
KCNH2 Q12809 2/20 0.34
MGLL Q99685 3/20 0.33
HSD11B1 P28845 1/20 0.33
HDAC4 P56524 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13072734 0.97 HTR2B (0.37) L3MBTL1RAD52UBE2NTPSAB1TPSD1
Trifluoroacetic Acid SCHEMBL380667 0.91 RAD52 (0.39) L3MBTL1RAD52UBE2NTPSAB1TPSD1
SCHEMBL208372 0.88 HSD11B1 (0.41) L3MBTL1HTR2BSPRL3MBTL3NAMPT
SCHEMBL208558 0.88 HTR2B (0.37) HTR2BSPRNAMPTMGLLHSD11B1
SCHEMBL208557 0.88 HTR2B (0.37) HTR2BSPRNAMPTMGLLHSD11B1
SCHEMBL3127709 0.88 HRH3 (0.37) HTR2BSPRNAMPTMGLLHSD11B1
SCHEMBL3127712 0.88 HRH3 (0.37) HTR2BSPRNAMPTMGLLHSD11B1
SCHEMBL208929 0.88 HTR2B (0.37) HTR2BSPRNAMPTMGLLHSD11B1
SCHEMBL3125447 0.88 HRH3 (0.37) HTR2BSPRNAMPTMGLLHSD11B1
SCHEMBL208559 0.88 HTR2B (0.37) HTR2BSPRNAMPTMGLLHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049513-B1 PIPERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 LILLY CO ELI (US) 2012-01-25 EP disclosed
US-7829582-B2 Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 ELI LILLY AND COMPANY (US) 2010-11-09 US disclosed
EP-2049513-A1 PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 Eli Lilly & Company (US) 2009-04-22 EP disclosed
US-20090088430-A1 PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY 2009-04-02 US disclosed
WO-2007127901-A1 PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 ELI LILLY AND COMPANY (US) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088430-A1 PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 HSD11B1, HSD17B1, HSD3B1 L3MBTL1 3422/4885RAD52 4462/4885UBE2N 3305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.